Pharmacotherapy of giant cell arteritis and polymyalgia rheumatica: Prospects for the use of monoclonal antibodies to interleukin 6

Giant cell arteritis (GCA) and polymyalgia rheumatica (RPM) are immune-mediated rheumatic disease (IMRDs), which typically develop in people over 50 years of age. Currently, GCA and PMR are considered within a single complex autoimmune-autoinflammatory pathology, defined as “GCA-PMR spectrum disease...

Descripció completa

Dades bibliogràfiques

Autors principals:	Evgeny L. Nasonov, Azamat M. Satybaldyev, Elvira N. Otteva, Tatiana V. Beketova, Andrey A. Baranov
Format:	Artigo
Idioma:	Russo
Publicat:	IMA PRESS LLC 2024-09-01
Col·lecció:	Научно-практическая ревматология
Matèries:	giant cell arteritis polymyalgia rheumatica interleukin 6 interleukin 6 inhibitors tocilizumab
Accés en línia:	https://rsp.mediar-press.net/rsp/article/view/3600
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!